TY - JOUR AU - Advani, A. AU - Coiffier, B. AU - Czuczman, M. S. AU - Dreyling, M. AU - Foran, J. AU - Gine, E. PY - 2010 DA - 2010// TI - Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.25.1900 DO - 10.1200/JCO.2009.25.1900 ID - Advani2010 ER - TY - JOUR AU - Alley, S. C. AU - Okeley, N. M. AU - Senter, P. D. PY - 2010 DA - 2010// TI - Antibody-drug conjugates: targeted drug delivery for cancer JO - Curr Opin Chem Biol VL - 14 UR - https://doi.org/10.1016/j.cbpa.2010.06.170 DO - 10.1016/j.cbpa.2010.06.170 ID - Alley2010 ER - TY - JOUR AU - Carrasco-Triguero, M. AU - Yi, J. H. AU - Dere, R. AU - Qiu, Z. J. AU - Lei, C. AU - Li, Y. PY - 2013 DA - 2013// TI - Immunogenicity assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine JO - Bioanalysis VL - 5 UR - https://doi.org/10.4155/bio.13.64 DO - 10.4155/bio.13.64 ID - Carrasco-Triguero2013 ER - TY - STD TI - Center for Drug Evaluation and Research, US Food and Drug Administration. Guidance for Industry: Assay Development for Immunogenicity Testing of Therapeutic Proteins. 2009. http://www.bioagilytix.com/wp-content/uploads/2016/02/FDA-GUIDANCE-Assay-Development-Immunogenicity-Testing.pdf. Accessed 27 June 2017. UR - http://www.bioagilytix.com/wp-content/uploads/2016/02/FDA-GUIDANCE-Assay-Development-Immunogenicity-Testing.pdf ID - ref4 ER - TY - STD TI - Committee for Medicinal Products for Human Use. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. London: European Medicines Agency; December 13, 2007. EMEA/CHMP/BMWP/14327/2006 ID - ref5 ER - TY - JOUR AU - DeAngelo, D. AU - Stock, W. AU - Stein, A. AU - Shustov, A. AU - Liedtke, M. AU - Schiffer, C. PY - 2017 DA - 2017// TI - Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study JO - Blood Adv VL - 1 UR - https://doi.org/10.1182/bloodadvances.2016001925 DO - 10.1182/bloodadvances.2016001925 ID - DeAngelo2017 ER - TY - JOUR AU - Fayad, L. AU - Offner, F. AU - Smith, M. R. AU - Verhoef, G. AU - Johnson, P. AU - Kaufman, J. L. PY - 2013 DA - 2013// TI - Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.42.7211 DO - 10.1200/JCO.2012.42.7211 ID - Fayad2013 ER - TY - JOUR AU - Gorovits, B. AU - Wakshull, E. AU - Pillutla, R. AU - Xu, Y. AU - Manning, M. S. AU - Goyal, J. PY - 2014 DA - 2014// TI - Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics JO - J Immunol Methods VL - 408 UR - https://doi.org/10.1016/j.jim.2014.05.010 DO - 10.1016/j.jim.2014.05.010 ID - Gorovits2014 ER - TY - JOUR AU - Hock, M. B. AU - Thudium, K. E. AU - Carrasco-Triguero, M. AU - Schwabe, N. F. PY - 2015 DA - 2015// TI - Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality JO - AAPS J VL - 17 UR - https://doi.org/10.1208/s12248-014-9684-6 DO - 10.1208/s12248-014-9684-6 ID - Hock2015 ER - TY - JOUR AU - Hoofring, S. A. AU - Lopez, R. AU - Hock, M. B. AU - Kaliyaperumal, A. AU - Patel, S. K. AU - Swanson, S. J. PY - 2013 DA - 2013// TI - Immunogenicity testing strategy and bioanalytical assays for antibody-drug conjugates JO - Bioanalysis VL - 5 UR - https://doi.org/10.4155/bio.13.10 DO - 10.4155/bio.13.10 ID - Hoofring2013 ER - TY - JOUR AU - Jani, D. AU - Marsden, R. AU - Mikulskis, A. AU - Gleason, C. AU - Klem, T. AU - Krinos Fiorotti, C. PY - 2015 DA - 2015// TI - Recommendations for the development and validation of confirmatory anti-drug antibody assays JO - Bioanalysis VL - 7 UR - https://doi.org/10.4155/bio.15.96 DO - 10.4155/bio.15.96 ID - Jani2015 ER - TY - JOUR AU - Kantarjian, H. M. AU - DeAngelo, D. J. AU - Stelljes, M. AU - Martinelli, G. AU - Liedtke, M. AU - Stock, W. PY - 2016 DA - 2016// TI - Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1509277 DO - 10.1056/NEJMoa1509277 ID - Kantarjian2016 ER - TY - JOUR AU - Koren, E. AU - Zuckerman, L. A. AU - Mire-Sluis, A. R. PY - 2002 DA - 2002// TI - Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction JO - Curr Pharm Biotechnol VL - 3 UR - https://doi.org/10.2174/1389201023378175 DO - 10.2174/1389201023378175 ID - Koren2002 ER - TY - JOUR AU - Ogura, M. AU - Tobinai, K. AU - Hatake, K. AU - Davies, A. AU - Crump, M. AU - Ananthakrishnan, R. PY - 2016 DA - 2016// TI - Phase I study of inotuzumab ozogamicin combined with R-CVP for relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-2488 DO - 10.1158/1078-0432.CCR-15-2488 ID - Ogura2016 ER - TY - JOUR AU - Sauerborn, M. AU - van Dongen, W. PY - 2014 DA - 2014// TI - Practical considerations for the pharmacokinetic and immunogenic assessment of antibody-drug conjugates JO - BioDrugs VL - 28 UR - https://doi.org/10.1007/s40259-014-0096-z DO - 10.1007/s40259-014-0096-z ID - Sauerborn2014 ER - TY - JOUR AU - Shankar, G. AU - Devanarayan, V. AU - Amaravadi, L. AU - Barrett, Y. C. AU - Bowsher, R. AU - Finco-Kent, D. PY - 2008 DA - 2008// TI - Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products JO - J Pharm Biomed Anal VL - 48 UR - https://doi.org/10.1016/j.jpba.2008.09.020 DO - 10.1016/j.jpba.2008.09.020 ID - Shankar2008 ER - TY - JOUR AU - Shor, B. AU - Gerber, H. P. AU - Sapra, P. PY - 2015 DA - 2015// TI - Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies JO - Mol Immunol VL - 67 UR - https://doi.org/10.1016/j.molimm.2014.09.014 DO - 10.1016/j.molimm.2014.09.014 ID - Shor2015 ER - TY - JOUR AU - Sievers, E. L. AU - Larson, R. A. AU - Stadtmauer, E. A. AU - Estey, E. AU - Lowenberg, B. AU - Dombret, H. PY - 2001 DA - 2001// TI - Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse JO - J Clin Oncol VL - 19 UR - https://doi.org/10.1200/JCO.2001.19.13.3244 DO - 10.1200/JCO.2001.19.13.3244 ID - Sievers2001 ER - TY - JOUR AU - Teicher, B. A. AU - Chari, R. V. PY - 2011 DA - 2011// TI - Antibody conjugate therapeutics: challenges and potential JO - Clin Cancer Res VL - 17 UR - https://doi.org/10.1158/1078-0432.CCR-11-1417 DO - 10.1158/1078-0432.CCR-11-1417 ID - Teicher2011 ER - TY - STD TI - Wensel DL, Awwad M, inventors. Wyeth Corp., assignee. Elimination of interference in immunoassays caused by anti-carbohydrate antibodies.: South African patent CA2686206. May 7, 2012 ID - ref20 ER - TY - STD TI - Wyeth-Ayerst. Gemtuzumab Ozogamicin Summary for Presentation to the FDA’s Oncologic Division Advisory Committee 2000 http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3592b2c.pdf. Accessed 23 Jan 2017 UR - http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3592b2c.pdf ID - ref21 ER - TY - JOUR AU - Zein, N. AU - Sinha, A. M. AU - McGahren, W. J. AU - Ellestad, G. A. PY - 1988 DA - 1988// TI - Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically JO - Science VL - 240 UR - https://doi.org/10.1126/science.3240341 DO - 10.1126/science.3240341 ID - Zein1988 ER -